RxDoctor Payments Data

Raphael Louie, MD

Surgical Oncology · Richmond, VANPI 1730471764

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Leica Microsystems Inc. at 33.1% of the total. Reporting peaked in 2023 at $430 and has fallen 72.6% since, to $118 in 2025. That places this record below the midpoint for surgical oncology clinicians in VA, where the typical reported total is $3,034.

$919in general payments, 2019–2025

Across 9 payments — averaging $102.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Leica Microsystems Inc.$304
  • Endomagnetics Ltd$195
  • Mentor Worldwide LLC$134
  • Iovance Biotherapeutics, Inc.$123
  • Hologic Sales And Service, LLC$118
  • Axogen$46
$71,614in research payments, 2019–2025

Across 1 payment — averaging $71,614 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Iovance Biotherapeutics, Inc.$72K

What the payments were for

  • Food & beverage$919100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$919 in reported general payments places this provider in the 35th percentile of 28 surgical oncology providers in Virginia.

See all surgical oncology providers in Virginia

Medicare billing

Part B allowed, 2024
$127,330
Medicare patients
182
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other surgical oncology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →